Maintenance therapy after stem cell transplant for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your blood cancer from coming back. It is for people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or MDS/AML who have had or will have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML, MDS, or MDS/AML and are having or have had a stem cell transplant.
- Your bone marrow tests before transplant showed low levels of cancer cells (less than 5% for AML or MDS/AML, less than 10% for MDS).
- You are 18 years or older.
- You have adequate liver and kidney function (bilirubin below 2.0 mg/dL and creatinine clearance above 30 ml/min).
- You are in good physical condition (ECOG 0-1 or Karnofsky score at least 70).
- If you have already had the transplant, you must have engraftment (blood counts recovering) by day 50, no active infection, and no significant graft-versus-host disease (GVHD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a drug called VA (which includes a vitamin A derivative and a medication that helps the immune system fight cancer) after a stem cell transplant can help keep leukemia or MDS from coming back. It is for patients who are already in remission after their transplant.
This study tests whether adding venetoclax (a targeted pill that helps kill leukemia cells) to a stem cell transplant, and continuing it afterward, improves outcomes compared to a placebo. It is for people with acute myeloid leukemia (AML) in their first remission who are getting a reduced-intensity transplant.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.